A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Cerebral Adrenoleukodystrophy (cALD)
In brief
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy.
Key facts
- Study ID
- NCT05819866
- Run by
- Minoryx Therapeutics, S.L.
- People needed
- 40
- Starts
- 2023-07-12
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Stanford University Medical Center — Palo Alto, California, United States
- Kennedy Krieger Institute — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- University of Minnesota — Minneota, Minnesota, United States
- Hospital Austral — Buenos Aires, Argentina
- Federal University of Sao Paulo — São Paulo, Brazil
- ICM La Pitie Salpetriere — Paris, France
- Klinik und Poliklinik für Neurologie-Leipzig — Leipzig, Germany
- Sir Ganga Ram Hospital — New Delhi, India
- Hospital 12 de Octubre — Madrid, Spain
- National Hospital for Neurology and Neurosurgery — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.